Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Phase 2
120
about 1.3 years
18+
Male only
1 site in NY
What this study is about
Researchers are testing whether adding PSMA-based PET/CT to standard MRI improves the detection of clinically significant prostate cancer compared to MRI alone in men with low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The trial will assess how well the PET/CT scan matches up with the biopsy results and determine if it can help upgrade a diagnosis.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®)
- 2.Take Flotufolastat F18
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Diagnostic Agent (Positron Emitting Activity)
Secondary: Incremental detection rate of csPCa by PET/CT over MRI, Lesion-level concordance between rhPSMA-7.3 (¹⁸F) PET/CT, multiparametric MRI, and histopathology
imaging
Oncology